Clinical Report: Multimodal AI for Diabetes Care

Overview

This scoping review examines multimodal artificial intelligence (AI) in diabetes care, focusing on clinical applications, model architectures and fusion strategies, comparative performance, interpretability, and implementation barriers. The supplied article text describes the review rationale and methods but does not provide its search results or findings, so conclusions about included studies and performance cannot be reported.

Background

Diabetes affects an estimated 589 million adults worldwide, with the number projected to exceed 853 million by 2050. Its heterogeneous, multisystem nature means clinical assessment draws on varied information, whereas many existing AI systems address narrower tasks such as retinopathy screening or glucose risk stratification. Multimodal AI combines information from sources such as medical imaging, electronic health records, and sensor time series, but the literature has inconsistent terminology and varied approaches to data encoding and fusion. The review identifies limited consolidated evidence on performance relative to unimodal models and a need to examine interpretability and implementation barriers.

Data Highlights

Key Findings

• The review was designed to characterize multimodal AI applications spanning complication screening and personalized diabetes management.
• Its stated methodological scope includes encoder architectures, fusion strategies, model architectures, and explainability.
• The authors identify limited consolidated evidence on whether multimodal integration improves predictive performance over unimodal baselines; the supplied text does not report comparative results.
• The review highlights inconsistent use of multimodality terminology and increasingly varied data-encoding and fusion approaches as features of the literature.
• The supplied related-article summary reports that a separate scoping review of 82 multimodal AI studies found explainability methods lagging model development, with most models using post hoc techniques focused on individual inputs.
• The supplied context states that the ADA Standards of Care in Diabetes—2026 identify three FDA-cleared autonomous AI platforms for diabetic retinopathy screening: AEYE-DS, EyeArt, and LumineticsCore/IDx-DR.

Clinical Implications

The supplied review excerpt does not provide results sufficient to establish the clinical performance or utility of multimodal AI systems. The related guidance context states that diabetes technology selection should be individualized; the ADA 2026 Standards prefer automated insulin delivery over nonautomated pumps and multiple daily injections for people with type 1 diabetes, with device choice based on individual circumstances and preferences.

Conclusion

The review sets out to map multimodal AI methods and applications in diabetes while addressing comparative performance, interpretability, and implementation. Because the supplied article text ends before the review results, its evidence-based conclusions cannot be summarized here.

Related Resources & Content

1. American Diabetes Association, Diabetes Care, 2026 — Diabetes Technology: Standards of Care in Diabetes—2026
2. Frontiers in Endocrinology, 2026 — Integration of Digital Twins and Artificial Intelligence in Diabetes Management: Advancing from Mechanistic Insights to Comprehensive Precision Care
3. AACE Endocrine AI, 2026 — Scoping review identifies gaps in explainable AI
4. MDSpire News — AI's Expanding Role in Diabetes Care
5. aace endocrine ai — AI tools advance diabetes management
6. Diabetes Technology: Standards of Care in Diabetes—2026
7. Scoping review identifies gaps in explainable AI
8. Automated Insulin Delivery Systems in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis | Diabetes Care | American Diabetes Association
9. Challenges in and Opportunities for Individualizing Diabetes Technology: A Position Statement by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group | Diabetes Care | American Diabetes Association